XTL Biopharmaceutica (Israel) Performance
| XTLB Stock | ILS 9.00 0.00 0.00% |
XTL Biopharmaceutica holds a performance score of 12 on a scale of zero to a hundred. The firm maintains a market beta of 5.34, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, XTL Biopharmaceutica will likely underperform. Use XTL Biopharmaceuticals total risk alpha, treynor ratio, value at risk, as well as the relationship between the sortino ratio and maximum drawdown , to analyze future returns on XTL Biopharmaceuticals.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in XTL Biopharmaceuticals are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, XTL Biopharmaceutica sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Total Cashflows From Investing Activities | 8000.00 |
XTL |
XTL Biopharmaceutica Relative Risk vs. Return Landscape
If you would invest 320.00 in XTL Biopharmaceuticals on January 25, 2024 and sell it today you would earn a total of 580.00 from holding XTL Biopharmaceuticals or generate 181.25% return on investment over 90 days. XTL Biopharmaceuticals is generating 3.5823% of daily returns and assumes 21.7895% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than XTL on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
XTL Biopharmaceutica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for XTL Biopharmaceutica's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as XTL Biopharmaceuticals, and traders can use it to determine the average amount a XTL Biopharmaceutica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1644
| Best Portfolio | Best Equity | |||
| Good Returns | XTLB | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 21.79 actual daily | 96 96% of assets are less volatile |
Expected Return
| 3.58 actual daily | 70 70% of assets have lower returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average XTL Biopharmaceutica is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of XTL Biopharmaceutica by adding it to a well-diversified portfolio.
XTL Biopharmaceutica Fundamentals Growth
XTL Stock prices reflect investors' perceptions of the future prospects and financial health of XTL Biopharmaceutica, and XTL Biopharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on XTL Stock performance.
| Return On Equity | 0.38 | |||
| Return On Asset | -0.1 | |||
| Current Valuation | 61.84 M | |||
| Shares Outstanding | 514.21 M | |||
| Price To Earning | 558.33 X | |||
| EBITDA | (940 K) | |||
| Cash And Equivalents | 5.06 M | |||
| Cash Per Share | 0.01 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (1.05 M) | |||
About XTL Biopharmaceutica Performance
To evaluate XTL Biopharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when XTL Biopharmaceutica generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare XTL Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand XTL Biopharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents XTL's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel. XTL BIOPHARMACEUTI is traded on Tel Aviv Stock Exchange in Israel.Things to note about XTL Biopharmaceuticals performance evaluation
Checking the ongoing alerts about XTL Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for XTL Biopharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| XTL Biopharmaceutica is way too risky over 90 days horizon | |
| XTL Biopharmaceutica appears to be risky and price may revert if volatility continues | |
| XTL Biopharmaceutica has high likelihood to experience some financial distress in the next 2 years | |
| XTL Biopharmaceuticals has accumulated about 5.06 M in cash with (1.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 16.0% of the company outstanding shares are owned by insiders |
- Analyzing XTL Biopharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether XTL Biopharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining XTL Biopharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating XTL Biopharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of XTL Biopharmaceutica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of XTL Biopharmaceutica's stock. These opinions can provide insight into XTL Biopharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for XTL Stock analysis
When running XTL Biopharmaceutica's price analysis, check to measure XTL Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XTL Biopharmaceutica is operating at the current time. Most of XTL Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of XTL Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XTL Biopharmaceutica's price. Additionally, you may evaluate how the addition of XTL Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |